Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
Last verified by NonDilute: 2026-04-29. Official notice and agency instructions control.
If your team has validated mechanistic insight into cancer treatment side effects and can design a longitudinal clinical study to identify predictive biomarkers, this R01 can fund a 5-year program to derisk your intervention concept.
Report stale or inaccurate summary
What this is
This NIH R01 opportunity funds collaborative teams studying adverse effects that persist after cancer therapy—cardiotoxicity, cognitive impairment, secondary malignancies, and other chronic sequelae. Successful applications combine mechanistic research with longitudinal clinical phenotyping to validate biomarkers, imaging, and patient-reported outcomes as endpoints for future intervention trials. Strong proposals integrate basic, translational, and clinical science to move from mechanism to therapeutic strategy.
Who can apply
Eligible applicants include universities, nonprofits (501(c)(3) or unincorporated), small businesses, for-profit companies, and all levels of government (state, county, city, tribal). Domestic institutions eligible; no geography restriction stated. Collaborative multi-institutional teams strongly encouraged.
Eligible applicant types
- Special district governments
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Private institutions of higher education
- Independent school districts
- Small businesses
- Public and State controlled institutions of higher education
- Native American tribal organizations (other than Federally recognized tribal governments)
- County governments
- Public housing authorities/Indian housing authorities
- Native American tribal governments (Federally recognized)
- State governments
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- City or township governments
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- For profit organizations other than small businesses
Full description — from the agency
The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.
Topics: cancer therapy adverse effects · cardiotoxicity · treatment sequelae · clinical biomarkers · translational research · long-term cancer outcomes
Public-source funding discovery only. This summary is generated from public agency data and may be incomplete or stale. NonDilute is not affiliated with, endorsed by, or acting on behalf of any government agency. Official notices and agency instructions control. NonDilute does not determine eligibility, provide grant-writing advice, or guarantee funding.